China Says No To India’s Proposal For Rupee-Renminbi Trade

China has not accepted India's proposal to carry out bilateral trade in local currencies which was aimed at bridging the ballooning trade deficit with the neighbouring country, an official said.

India's exports to China stood at $13.4 billion, imports aggregated to $76.4 billion in 2017-18, leaving a trade deficit of $63 billion. It was $51.11 billion in 2016-17.

India had suggested China for renminbi-rupee trade to boost its exports and tackle the widening trade deficit.

"They have not accepted the proposal," the official said.

The issue was discussed in an inter-ministerial meeting in October. In the meeting, it was suggested to the Reserve Bank of India and the Department of Economic Affairs to look at the possibility of exploring renminbi-rupee trade with China.

India has also proposed trade in national currencies with some other countries, including Russia, Iran and Venezuela. New Delhi has trade deficit with these three countries, too.

The Federation of Indian Export Organisations President Ganesh Kumar Gupta said that the government should promote exports from India in the domestic currency.

"This will help in bridging trade deficit with countries like China," Gupta said.

Trade experts have stated that bilateral trade in domestic currencies will help India only in the case of those countries with which it has a trade balance.

"Trade imbalance should not be there with the country with which we want to do trade in rupee. It will not help in bridging the deficit. The partner country should have an opportunity to invest in India to use the rupee," said Biswajit Dhar, professor at Jawaharlal Nehru University.

The Indian industry and exporters have time and again raised the issue of increasing trade deficit with China and have asked the government to seek greater market access for domestic goods in the Chinese market.

Recently, China has permitted exports of rice and sugar. But India wants to increase exports of several other items, including pharmaceuticals, engineering and services.